about
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesEvolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathologyFCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signalingDefining the immunological phenotype of Fc receptor-like B (FCRLB) deficient mice: Confounding role of the inhibitory FcγRIIbProteomics and Transcriptomics of BJAB Cells Expressing the Epstein-Barr Virus Noncoding RNAs EBER1 and EBER2FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling.Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applicationsTH17, TH22 and Treg cells are enriched in the healthy human cecum.The Xenopus FcR family demonstrates continually high diversification of paired receptors in vertebrate evolution.Fc receptors for immunoglobulins and their appearance during vertebrate evolutionRecognition of additional roles for immunoglobulin domains in immune functionExpression of the autoimmune susceptibility gene FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell death-1.Molecular underpinning of B-cell anergy.Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling.A refined study of FCRL genes from a genome-wide association study for Graves' disease.FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy.FCRL3 gene polymorphisms confer autoimmunity risk for allergic rhinitis in a Chinese Han populationGenetic factors of autoimmune thyroid diseases in JapaneseInvolvement of the HCK and FGR src-family kinases in FCRL4-mediated immune regulationAssociation of Fc receptor-like 5 (FCRL5) with Graves' disease is secondary to the effect of FCRL3.Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment.Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin.Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarrayGenomic and functional characterization of the diverse immunoglobulin domain-containing protein (DICP) familyA functional variant in FCRL3 is associated with higher Fc receptor-like 3 expression on T cell subsets and rheumatoid arthritis disease activity.Pooled genome wide association detects association upstream of FCRL3 with Graves' disease.Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo.Genome-wide comparison of FGFRL1 with structurally related surface receptors.FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxinsFCRL regulation in innate-like B cells.Characterization of human FCRL4-positive B cells.FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.Integrative genomic deconvolution of rheumatoid arthritis GWAS loci into gene and cell type associations.Cutting edge: FcR-like 6 is an MHC class II receptor.Phosphatase regulation of immunoreceptor signaling in T cells, B cells and mast cells.Fc Receptor-Like Proteins in Pathophysiology of B-cell DisorderPolymorphisms of FCRL3 in a Chinese population with Vogt-Koyanagi-Harada (VKH) syndromeFCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemiaFc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells.Overexpression of Fc receptor-like 1 associated with B-cell activation during hepatitis B virus infection
P2860
Q28069362-AA87E785-3BBD-4092-B0B3-9695BDB29314Q28287124-F5ED4206-39B5-41DA-A0DB-876EAE366791Q28506777-4770E95E-CCA2-4996-BC93-6E7D660793D6Q28512262-597D8BE0-C8E0-487C-AC4B-DB2C7EB28333Q28545914-8C3C1BE2-F200-413A-A4D3-FE0DB2F2B16EQ30423426-F3D54D51-84A4-4E1D-A223-71EE75D46D89Q30834514-7ACB925E-1F38-4A13-AD4D-64754C31C367Q31076852-257A4E41-C7F5-4601-BB54-C514CAD532A7Q33335321-58F3EE1C-FB5B-4477-BB7A-5FA3C84A9EC7Q33591097-228995E7-5681-4158-B2D4-C21C8E3B67B6Q33664936-CDA8E8DD-552F-4D37-AC1B-448E21679AE7Q33951920-19F8A1EB-8550-4F1C-BA43-9380113B450FQ34262298-27B5D675-7A41-4818-A45C-6A1C65DC4350Q34499276-08C33546-1AB5-44C4-B71E-B8F3D408E3B0Q34625570-1BC1C6A0-8914-4167-A553-E3EF9CD57FE5Q34674784-A4CD7C08-263E-40FA-A353-E68285AEFE02Q34977535-E7AD7F79-DCBD-44F8-95B4-097F395E2FFEQ35661517-BFE3BF9C-2470-40A0-B149-C252F35A4DCBQ35686107-4EC883D1-5E2A-4C88-8F7F-53854896050AQ35822169-6140318A-E6DB-4AEE-A510-8BC114CBF361Q35834538-5A02896F-0731-4D56-A47A-7323FF303413Q35876904-E01357C0-5B95-4820-9765-77C317D9C3EAQ35945962-4110E2EF-1FF7-4360-9C23-FA9D095FF813Q35957413-49812B7E-D579-414E-A3D2-EFBF685551E7Q36028278-6702A5AF-FDB0-4758-93E6-DAF31C48C32AQ36198104-599368DE-F063-4725-92B7-F43E79EB9D58Q36229611-9BD07FF7-5E5F-46A7-A405-313AEBEDE764Q36375206-BA0A9061-BF07-4898-8F3F-A497893D5714Q36384641-014C4D7D-CDE5-42BA-84B8-5426409D0EEDQ36402651-A825E845-9417-4A79-8244-101468BF7403Q36411427-74C5C456-E387-40AE-8885-68C01DDFCE66Q36732806-3DB75865-CDFE-4C86-88EE-FC3C0BAB4F6CQ36860748-D894FC16-8196-41F0-892C-97CB7861970FQ36926291-5D5E1F1D-8BB0-4907-BCFE-65B2BACBF266Q37066101-08CB4CBD-629E-498E-A526-6E87BA908BFFQ37108980-B8C633CF-95D6-4343-82CD-5FDD0EB71DEAQ37194571-3F407D93-2E2C-4FC4-A83F-A08D2A24AAF1Q37343462-C6F6B800-3545-4EE2-81FC-9E5F74BD434FQ37349656-A98C7289-4BDB-40BF-9234-96175A2A4EECQ37371002-147BD1EF-58D1-48A8-947C-F5F87BF8F6B7
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Fc receptor-like molecules
@ast
Fc receptor-like molecules
@en
Fc receptor-like molecules
@nl
type
label
Fc receptor-like molecules
@ast
Fc receptor-like molecules
@en
Fc receptor-like molecules
@nl
prefLabel
Fc receptor-like molecules
@ast
Fc receptor-like molecules
@en
Fc receptor-like molecules
@nl
P3181
P1476
Fc receptor-like molecules
@en
P2093
Randall S Davis
P304
P3181
P356
10.1146/ANNUREV.IMMUNOL.25.022106.141541
P407
P577
2007-01-01T00:00:00Z